Skip to main content
EVENTS

America’s Opioid Epidemic

From Evidence to Impact

Monday, October 30, 2017 - The Clinton Foundation and The Johns Hopkins Bloomberg School of Public Health Invite you to : America's Opioid Epidemic: From Evidence to Impact

 

    America’s Opioid Epidemic

    From Evidence to Impact

    Monday, October 30, 2017
    10:00 a.m. - 12:30 p.m.
    Johns Hopkins Bloomberg School of Public Health
    Sommer Hall
    615 N. Wolfe Street
    Baltimore, MD 21205  

    October 30, 2017 Cover for The Opioid Epidemic: From Evidence to Impact report

    The U.S. is experiencing its highest-ever rates of opioid addiction and overdose, and the numbers are only predicted to rise. A combination of the overuse of prescription opioids for acute and chronic pain and an increasing supply of heroin and illicit fentanyl is driving this epidemic.

    Evidence-based strategies for preventing and treating opioid addiction have been shown to be successful but are not being implemented quickly and at scale. On October 30, 2017, the Clinton Health Matters Initiative and the Johns Hopkins Bloomberg School of Public Health co-hosted a forum focused on elevating high-impact solutions to the nation’s opioid epidemic.

    Speakers, panelists, and thought leaders representing diverse stakeholders affected by the crisis considered critical components needed to reduce the injury and death rates nationwide. Evidence-based recommendations that reflect the most current science were the focus, and translating that evidence to action was the goal.

    Speakers & Panelists

    • Ellen J. MacKenzie, PhD ’79, MSc ’75, Dean, Johns Hopkins Bloomberg School of Public Health
    • Elijah Cummings, U.S. Congressman, Maryland’s 7th District
    • President Bill Clinton, Founder and Board Chair, Clinton Foundation; 42nd President of the United States
    • G. Caleb Alexander, MD, MS, Co-Director, Johns Hopkins Center for Drug Safety and Effectiveness
    • Michael Botticelli, MEd, Executive Director, Grayken Center for Addiction at Boston Medical Center; Distinguished Policy Scholar, Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management; Former Director of National Drug Control Policy
    • Carol Forster, MD, Physician Director, Pharmacy & Therapeutics/Medication Safety, Mid-Atlantic Permanente Medical Group
    • Tom Geddes, CEO, Plank Industries
    • Andrea Gielen, ScD, Director, Johns Hopkins Center for Injury Research and Policy
    • Jim Hood, CEO, Facing Addiction
    • Erica Poellot, Project Director, Shaping Sanctuary, Senior Community Minister, Judson Memorial Church, Director of Faith and Community Partnerships, Harm Reduction Coalition
    • Tom Synan, Chief of Police, Newtown, Ohio
    • Randi Weingarten, President, American Federation of Teachers
    • Leana Wen, MD, MSc, FAAEM, Baltimore City Health Commissioner

    Follow this important conversation on Twitter @JohnsHopkinsSPH #OpioidSummit.

    More Information

    Email: jhsph.events@jhu.edu

    Event Sponsors

    America’s Opioid Epidemic: From Evidence to Impact

    October 30, 2017

    The U.S. is experiencing its highest-ever rates of opioid addiction and overdose, and the numbers are only predicted to rise. A combination of the overuse of prescription opioids for acute and chronic pain and an increasing supply of heroin and illicit fentanyl is driving this epidemic.

    Evidence-based strategies for preventing and treating opioid addiction have been shown to be successful but are not being implemented quickly and at scale. On October 30, 2017, the Clinton Health Matters Initiative and the Johns Hopkins Bloomberg School of Public Health will co-host a forum focused on elevating high-impact solutions to the nation’s opioid epidemic.

    Speakers, panelists, and thought leaders representing diverse stakeholders affected by the crisis will consider critical components needed to reduce the injury and death rates nationwide. Evidence-based recommendations that reflect the most current science will be the focus, and translating that evidence to action will be the goal.